The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Makrolon polycarbonate is key to needle-free injections that can stand up to sterilization
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
Ind-Ra maintains a neutral outlook for healthcare in FY23
Subscribe To Our Newsletter & Stay Updated
